Cellular and molecular mechanisms of metformin: an overview
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
Considerable efforts have been made since the 1950s to better understand the cellular and molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now recommended as the first-line oral therapy for T2D (Type 2 diabetes). The main effect of this drug from the biguanide family is to acutely decrease hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory chain complex I. In addition, the resulting decrease in hepatic energy status activates AMPK (AMP-activated protein kinase), a cellular metabolic sensor, providing a generally accepted mechanism for the action of metformin on hepatic gluconeogenesis. The demonstration that respiratory chain complex I, but not AMPK, is the primary target of metformin was recently strengthened by showing that the metabolic effect of the drug is preserved in liver-specific AMPK-deficient mice. Beyond its effect on glucose metabolism, metformin has been reported to restore ovarian function in PCOS (polycystic ovary syndrome), reduce fatty liver, and to lower microvascular and macrovascular complications associated with T2D. Its use has also recently been suggested as an adjuvant treatment for cancer or gestational diabetes and for the prevention in pre-diabetic populations. These emerging new therapeutic areas for metformin will be reviewed together with recent findings from pharmacogenetic studies linking genetic variations to drug response, a promising new step towards personalized medicine in the treatment of T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In PCOS, metformin reduces insulin resistance and inhibits ovarian androgen production via effects on steroidogenic acute regulatory protein and 17alphahydroxylase (Diamanti-Kandarakis et al. , 2010; Viollet et al. , 2012).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Viollet et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“a drug that is currently being used to treat type II diabetic patients, metformin [74], can activate AMPK”
From Senescence of T Lymphocytes: Implications for Enhancing Human Immunity (2016) · cites this paper as [74]
The cited source says what the claim attributes to it.
In the citing paper
“Given the evidence that metformin acts through the mitochondrial electron transport chain (ETC) by inhibiting complex I(46, 210–212) (Figure 8)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [46]
In the citing paper
“By far the most important mechanism is the reduction in hepatic glucose production that is considered mediated by the activation of the global energy sensor in cells, adenosine monophosphate-activated protein kinase (AMPK) (Figure 1).(46)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 4×
“Thus, AMPK activation by metformin induces the phosphorylation and inactivation of acetyl CoA carboxylase (ACC), an important rate-controlling enzyme for the synthesis of malonylCoA, which is both a critical precursor for the biosynthesis of fatty acids and a potent inhibitor of mitochondrial fatty acid oxidation [17].”
BackgroundInfluentialHyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Furthermore, the authors found a doseresponse relationship between duration of exposure to metformin and cancer incidence [106].”
BackgroundGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 25×
“Metformin most likely does not directly activate either LKB1 or AMPK as the drug does not influence the phosphorylation of AMPK by LKB1 in cell-free assay [21].”
BackgroundInfluential
Cited by
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Self-citationClinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00006 · Cited by 1,500
Durham, A. L., Speer, M. Y., Scatena, M., Giachelli, C. M., & Shanahan, C. M. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy010 · Cited by 1,093
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
Wheaton, W. W., Weinberg, S. E., Hamanaka, R. B., Soberanes, S., Sullivan, L. B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G. M., Budigner, G. S., et al. (2014) · eLife · doi:10.7554/elife.02242 · Cited by 1,105
“Metformin suppresses liver gluconeogenesis thereby reducing glucose release from the liver (Inzucchi et al., 1998; Viollet et al., 2012).”
Epigenetic mechanisms of longevity and aging
Sen, P., Shah, P. P., Nativio, R., & Berger, S. L. (2016) · Cell · doi:10.1016/j.cell.2016.07.050 · Cited by 956
Fullerton, M. D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.-P., O'Neill, H. M., Ford, R. J., Palanivel, R., O'Brien, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3372 · Cited by 893
AMPK, insulin resistance, and the metabolic syndrome
Ruderman, N. B., Carling, D., Prentki, M., & Cacicedo, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67227 · Cited by 873
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Cha, J.-H., Yang, W.-H., Xia, W., Wei, Y., Chan, L.-C., Lim, S.-O., Li, C.-W., Kim, T., Chang, S.-S., Lee, H.-H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.030 · Cited by 773
Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes
Lee, H.-M., Kim, J.-J., Kim, H. J., Shong, M., Ku, B. J., & Jo, E.-K. (2013) · Diabetes · doi:10.2337/db12-0420 · Cited by 734
Anti-inflammatory effects of metformin irrespective of diabetes status
Cameron, A. R., Morrison, V. L., Levin, D., Mohan, M., Forteath, C., Beall, C., McNeilly, A. D., Balfour, D. J. K., Savinko, T., Wong, A. K. F., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308445 · Cited by 704
“The key clinical hallmark of metformin’s antihyperglycemic action is suppression of hepatocyte gluconeogenesis.(4,5,9) The most likely cellular effect underlying this response is inhibition of mitochondrial enzymes, including complex I in the electron transport chain.”
Self-citationKenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
The Origins and Drivers of Insulin Resistance
Johnson, A. M. F., & Olefsky, J. M. (2013) · Cell · doi:10.1016/j.cell.2013.01.041 · Cited by 643
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
Schalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
AMPK as a Therapeutic Target for Treating Metabolic Diseases
Day, E. A., Ford, R. J., & Steinberg, G. R. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.05.004 · Cited by 619
Normalization of CD4 + T cell metabolism reverses lupus
Yin, Y., Choi, S.-C., Xu, Z., Perry, D. J., Seay, H., Croker, B. P., Sobel, E. S., Brusko, T. M., & Morel, L. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0835 · Cited by 607
Metformin and Its Benefits for Various Diseases
Lv, Z., & Guo, Y. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00191 · Cited by 535
Metformin as adjunct antituberculosis therapy
Singhal, A., Jie, L., Kumar, P., Hong, G. S., Leow, M. K.-S., Paleja, B., Tsenova, L., Kurepina, N., Chen, J., Zolezzi, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009885 · Cited by 547
Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning
Pollak, M. N. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0263 · Cited by 507
Metformin pathways: pharmacokinetics and pharmacodynamics
Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283559b22 · Cited by 495
Metformin in Cancer Treatment and Prevention
Morales, D. R., & Morris, A. D. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-062613-093128 · Cited by 484
Molecular mechanism of action of metformin: old or new insights?
Rena, G., Pearson, E. R., & Sakamoto, K. (2013) · Diabetologia · doi:10.1007/s00125-013-2991-0 · Cited by 479
Gut microbiome and type 2 diabetes: where we are and where to go?
Sharma, S., & Tripathi, P. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.10.003 · Cited by 428
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Wu, Q., Jiang, L., Li, S.-C., He, Q.-J., Yang, B., & Cao, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0366-x · Cited by 414
The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor
D’Oria, R., Schipani, R., Leonardini, A., Natalicchio, A., Perrini, S., Cignarelli, A., Laviola, L., & Giorgino, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5732956 · Cited by 376
Metformin Activates a Duodenal Ampk-Dependent Pathway to Lower Hepatic Glucose Production in Rats
Duca, F. A., Côté, C. D., Rasmussen, B. A., Zadeh-Tahmasebi, M., Rutter, G. A., Filippi, B. M., & Lam, T. K. T. (2015) · Nature Medicine · doi:10.1038/nm.3787 · Cited by 402
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Saraei, P., Asadi, I., Kakar, M. A., & Moradi-Kor, N. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200059 · Cited by 350
The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases
Maessen, D. E. M., Stehouwer, C. D. A., & Schalkwijk, C. G. (2015) · Clinical Science · doi:10.1042/cs20140683 · Cited by 334
New Insights into Neutrophil Extracellular Traps: Mechanisms of Formation and Role in Inflammation
Yang, H., Biermann, M. H., Brauner, J. M., Liu, Y., Zhao, Y., & Herrmann, M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00302 · Cited by 337
Naderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv025 · Cited by 334
Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus
Blahova, J., Martiniakova, M., Babikova, M., Kovacova, V., Mondockova, V., & Omelka, R. (2021) · Pharmaceuticals · doi:10.3390/ph14080806 · Cited by 302
Wang, H., Li, T., Chen, S., Gu, Y., & Ye, S. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39296 · Cited by 325
“5 SLEDAI score $10 5 (9) 5 (9) Baseline SELENA-SLEDAI organ involvement CNS 0 (0) 0 (0) Serosal 0 (0) 0 (0) Hematologic 6 (11) 3 (5) Musculoskeletal 1 (2) 2 (4) Dermal 5 (9) 3 (5) Renal 7 (13) 8 (14) Proteinuria $1.”
BackgroundInfluentialReprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response
Zannella, V. E., Dal Pra, A., Muaddi, H., McKee, T. D., Stapleton, S., Sykes, J., Glicksman, R., Chaib, S., Zamiara, P., Milosevic, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1787 · Cited by 314
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
Ghrelin: much more than a hunger hormone
Pradhan, G., Samson, S. L., & Sun, Y. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328365b9be · Cited by 288
Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis
Kheirollahi, V., Wasnick, R. M., Biasin, V., Vazquez-Armendariz, A. I., Chu, X., Moiseenko, A., Weiss, A., Wilhelm, J., Zhang, J.-S., Kwapiszewska, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10839-0 · Cited by 293
Hydrogel-forming microneedles enhance transdermal delivery of metformin hydrochloride
Migdadi, E. M., Courtenay, A. J., Tekko, I. A., McCrudden, M. T. C., Kearney, M.-C., McAlister, E., McCarthy, H. O., & Donnelly, R. F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.009 · Cited by 279
Senescence of T Lymphocytes: Implications for Enhancing Human Immunity
Akbar, A. N., Henson, S. M., & Lanna, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.002 · Cited by 285
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Hostalek, U., Gwilt, M., & Hildemann, S. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278
Beier, U. H., Angelin, A., Akimova, T., Wang, L., Liu, Y., Xiao, H., Koike, M. A., Hancock, S. A., Bhatti, T. R., Han, R., et al. (2015) · The FASEB Journal · doi:10.1096/fj.14-268409 · Cited by 275
Herman, R., Kravos, N. A., Jensterle, M., Janež, A., & Dolžan, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031264 · Cited by 254
Repurposing metformin: an old drug with new tricks in its binding pockets
Pryor, R., & Cabreiro, F. (2015) · Biochemical Journal · doi:10.1042/bj20150497 · Cited by 280
Mohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278
Metformin as an Anticancer Agent
Vancura, A., Bu, P., Bhagwat, M., Zeng, J., & Vancurova, I. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.006 · Cited by 274
Hyaluronic acid and albumin based nanoparticles for drug delivery
Lei, C., Liu, X.-R., Chen, Q.-B., Li, Y., Zhou, J.-L., Zhou, L.-Y., & Zou, T. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.033 · Cited by 266
Understanding and overcoming metformin gastrointestinal intolerance
Bonnet, F., & Scheen, A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12854 · Cited by 256
Emerging Wastewater Contaminant Metformin Causes Intersex and Reduced Fecundity in Fish
Niemuth, N. J., & Klaper, R. D. (2015) · Chemosphere · doi:10.1016/j.chemosphere.2015.03.060 · Cited by 262
“…its introduction in the United States in 1995, due to its efficacy as an insulin sensitizer, the increasing number of cases of type-2 diabetes around the world (Viollet et al., 2012), and its recent recommendation as a therapy for prevention of type-2 diabetes (American Diabetes Association, 2013).”
BackgroundInfluentialMetformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice
Li, J., Deng, J., Sheng, W., & Zuo, Z. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.002 · Cited by 260
Naderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmv063 · Cited by 255
Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade
Dai, X., Bu, X., Gao, Y., Guo, J., Hu, J., Jiang, C., Zhang, Z., Xu, K., Duan, J., He, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.037 · Cited by 242
Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind
Infante, M., Leoni, M., Caprio, M., & Fabbri, A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.916 · Cited by 222
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches
Hussain, R., Zubair, H., Pursell, S., & Shahab, M. (2018) · Brain Sciences · doi:10.3390/brainsci8090177 · Cited by 229
Chen, L., Shu, Y., Liang, X., Chen, E. C., Yee, S. W., Zur, A. A., Li, S., Xu, L., Keshari, K. R., Lin, M. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314939111 · Cited by 237
Molecular Mechanisms and Signaling Pathways Involved in Sertoli Cell Proliferation
Meroni, S. B., Galardo, M. N., Rindone, G., Gorga, A., Riera, M. F., & Cigorraga, S. B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00224 · Cited by 229
Effects of metformin on weight loss: potential mechanisms
Malin, S. K., & Kashyap, S. R. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000095 · Cited by 223
“Unau Health | Lippincott Williams & Wilki and blocking gastrointestinal glucose absorption [3].”
BackgroundMetformin vs insulin in the management of gestational diabetes: a meta-analysis
Gui, J., Liu, Q., & Feng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064585 · Cited by 222
“The possible explanation might be that metformin has complex properties on endothelial functions and reactive oxygen species production [34], so as to reduce the endothelial activation and maternal inflammatory response of insulin resistance.”
BackgroundBrownfoot, F. C., Hastie, R., Hannan, N. J., Cannon, P., Tuohey, L., Parry, L. J., Senadheera, S., Illanes, S. E., Kaitu’u-Lino, T. J., & Tong, S. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.12.019 · Cited by 222
Metformin modulates hyperglycaemia‐induced endothelial senescence and apoptosis through SIRT1
Arunachalam, G., Samuel, S. M., Marei, I., Ding, H., & Triggle, C. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12496 · Cited by 221
“Metformin lowers blood glucose and improves insulin sensi- tivity by reducing hepatic gluconeogenesis via the activation of AMP-activated protein kinase)(AMPK) as well as promoting AMPK-mediated translocation of glucose transporter type 4 (Yang and Holman, 2006; Viollet et al., 2012).”
BackgroundKSR2 Mutations Are Associated with Obesity, Insulin Resistance, and Impaired Cellular Fuel Oxidation
Pearce, L. R., Atanassova, N., Banton, M. C., Bottomley, B., van der Klaauw, A. A., Revelli, J.-P., Hendricks, A., Keogh, J. M., Henning, E., Doree, D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.058 · Cited by 200
Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties
Picke, A.-K., Campbell, G., Napoli, N., Hofbauer, L. C., & Rauner, M. (2019) · Endocrine Connections · doi:10.1530/ec-18-0456 · Cited by 189
Fendt, S.-M., Bell, E. L., Keibler, M. A., Davidson, S. M., Wirth, G. J., Fiske, B., Mayers, J. R., Schwab, M., Bellinger, G., Csibi, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0080 · Cited by 199
Apostolova, N., Iannantuoni, F., Gruevska, A., Muntane, J., Rocha, M., & Victor, V. M. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101517 · Cited by 197
Haddad, P., Eid, H., Nachar, A., Thong, F., & Sweeney, G. (2015) · Pharmacognosy Magazine · doi:10.4103/0973-1296.149708 · Cited by 189
Adsorption of emerging contaminant metformin using graphene oxide
Zhu, S., Liu, Y.-G., Liu, S.-B., Zeng, G.-M., Jiang, L.-H., Tan, X.-F., Zhou, L., Zeng, W., Li, T.-T., & Yang, C.-P. (2017) · Chemosphere · doi:10.1016/j.chemosphere.2017.03.071 · Cited by 203
Yu, Z., Xu, C., Song, B., Zhang, S., Chen, C., Li, C., & Zhang, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04554-0 · Cited by 164
Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies
Zadra, G., Batista, J. L., & Loda, M. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0068 · Cited by 194
Molecular Mechanisms Modulating the Phenotype of Macrophages and Microglia
Amici, S. A., Dong, J., & Guerau-de-Arellano, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01520 · Cited by 191
Milardi, D., Gazit, E., Radford, S. E., Xu, Y., Gallardo, R. U., Caflisch, A., Westermark, G. T., Westermark, P., Rosa, C. L., & Ramamoorthy, A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00981 · Cited by 196
The Cellular and Molecular Basis of Translational Immunometabolism
Norata, G. D., Caligiuri, G., Chavakis, T., Matarese, G., Netea, M. G., Nicoletti, A., O’Neill, L. A. J., & Marelli-Berg, F. M. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.023 · Cited by 196
Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy
Kouidhi, S., Ben Ayed, F., & Benammar Elgaaied, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00353 · Cited by 196
Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects
Kamarudin, M. N. A., Sarker, M. M. R., Zhou, J.-R., & Parhar, I. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1495-2 · Cited by 191
Guidelines and Considerations for Metabolic Tolerance Tests in Mice
Benedé-Ubieto, R., Estévez-Vázquez, O., Ramadori, P., Cubero, F. J., & Nevzorova, Y. A. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s234665 · Cited by 172
The effects of metformin on autophagy
Lu, G., Wu, Z., Shang, J., Xie, Z., Chen, C., & zhang, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111286 · Cited by 173
Chan, S. M. H., Selemidis, S., Bozinovski, S., & Vlahos, R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.013 · Cited by 177
Mechanism of Metformin: A Tale of Two Sites
Song, R. (2016) · Diabetes Care · doi:10.2337/dci15-0013 · Cited by 178
Niemuth, N. J., Jordan, R., Crago, J., Blanksma, C., Johnson, R., & Klaper, R. D. (2014) · Environmental Toxicology and Chemistry · doi:10.1002/etc.2793 · Cited by 172
Insulin Resistance and Cancer: In Search for a Causal Link
Chiefari, E., Mirabelli, M., La Vignera, S., Tanyolaç, S., Foti, D. P., Aversa, A., & Brunetti, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011137 · Cited by 170
Zilinyi, R., Czompa, A., Czegledi, A., Gajtko, A., Pituk, D., Lekli, I., & Tosaki, A. (2018) · Molecules · doi:10.3390/molecules23051184 · Cited by 175
Løvvik, T. S., Carlsen, S. M., Salvesen, Ø., Steffensen, B., Bixo, M., Gómez-Real, F., Lønnebotn, M., Hestvold, K. V., Zabielska, R., Hirschberg, A. L., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30002-6 · Cited by 176
Hung, S. W., Zhang, R., Tan, Z., Chung, J. P. W., Zhang, T., & Wang, C. C. (2021) · Medicinal Research Reviews · doi:10.1002/med.21802 · Cited by 167
Jensterle Sever, M., Kocjan, T., Pfeifer, M., Kravos, N. A., & Janez, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0797 · Cited by 175
Chou, C.-C., Lee, K.-H., Lai, I.-L., Wang, D., Mo, X., Kulp, S. K., Shapiro, C. L., & Chen, C.-S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0135 · Cited by 170
Scheen, A. J., & Paquot, N. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.02.006 · Cited by 174
Geerling, J. J., Boon, M. R., van der Zon, G. C., van den Berg, S. A. A., van den Hoek, A. M., Lombès, M., Princen, H. M. G., Havekes, L. M., Rensen, P. C. N., & Guigas, B. (2014) · Diabetes · doi:10.2337/db13-0194 · Cited by 167
Self-citationEffect of Diet on Insulin Resistance in Polycystic Ovary Syndrome
Shang, Y., Zhou, H., Hu, M., & Feng, H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa425 · Cited by 171
The role of the endocannabinoid system in female reproductive tissues
Walker, O. S., Holloway, A. C., & Raha, S. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-018-0478-9 · Cited by 160
Xintaropoulou, C., Ward, C., Wise, A., Marston, H., Turnbull, A., & Langdon, S. P. (2015) · Oncotarget · doi:10.18632/oncotarget.4499 · Cited by 159
Hernández-Aguilera, A., Rull, A., Rodríguez-Gallego, E., Riera-Borrull, M., Luciano-Mateo, F., Camps, J., Menéndez, J. A., & Joven, J. (2013) · Mediators of Inflammation · doi:10.1155/2013/135698 · Cited by 160
Yue, W., Yang, C. S., DiPaola, R. S., & Tan, X.-L. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0337 · Cited by 160
Pathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
The Furan Fatty Acid Metabolite CMPF Is Elevated in Diabetes and Induces β Cell Dysfunction
Prentice, K. J., Luu, L., Allister, E. M., Liu, Y., Jun, L. S., Sloop, K. W., Hardy, A. B., Wei, L., Jia, W., Fantus, I. G., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.008 · Cited by 175
Androgen excess: Investigations and management
Lizneva, D., Gavrilova-Jordan, L. P., Walker, W., & Azziz, R. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.05.003 · Cited by 176
Metformin is associated with improved survival in endometrial cancer
Ko, E. M., Walter, P., Jackson, A., Clark, L., Franasiak, J., Bolac, C., Havrilesky, L. J., Secord, A. A., Moore, D. T., Gehrig, P. A., et al. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.021 · Cited by 158
The effect of environmental chemicals on the tumor microenvironment
Casey, S. C., Vaccari, M., Al-Mulla, F., Al-Temaimi, R., Amedei, A., Barcellos-Hoff, M. H., Brown, D. G., Chapellier, M., Christopher, J., Curran, C. S., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv035 · Cited by 152
p53 and metabolism: from mechanism to therapeutics
Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25267 · Cited by 171
Li, J., Gui, Y., Ren, J., Liu, X., Feng, Y., Zeng, Z., He, W., Yang, J., & Dai, C. (2016) · Scientific Reports · doi:10.1038/srep23975 · Cited by 152
Niu, C., Chen, Z., Kim, K., Sun, J. M., Xue, M., Chen, G., Li, S., Shen, Y., Zhu, Z., Wang, X., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1569913 · Cited by 158
Metadata
- Authors
- Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F.
- Affiliations
- INSERM, U1016, Institut Cochin, Paris, France
- Leiden University Medical Center (NL)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Leclerc, Jocelyne
- Foretz, Marc
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2011-11-11
- Volume
- 122
- Issue
- 6
- Pages
- 253-270
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- PMC
- PMC3398862
- OpenAlex
- W2154024784
- Cited by
- 1,720
- References
- 167
- Citations by year
- 2026: 63 · 2025: 85 · 2024: 96 · 2023: 103 · 2022: 106 · 2021: 143 · 2020: 155 · 2019: 135 · 2018: 141 · 2017: 156 · 2016: 137 · 2015: 144 · 2014: 117 · 2013: 104 · 2012: 34
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- metformin, type 2 diabetes, biguanides, AMPK, mitochondrial complex I inhibition, hepatic gluconeogenesis, hepatic glucose production, polycystic ovary syndrome, hepatic steatosis, diabetes complications, adjuvant cancer therapy, gestational diabetes mellitus, prediabetes, pharmacogenetics, personalized medicine
- MeSH terms
- Animals, Cardiovascular System, Diabetic Nephropathies, Female, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Polycystic Ovary Syndrome, Circadian Clocks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.